CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 82 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-07 | Schwartz Aharon Director | Purchase | +64,000 | $2.43 | $155K | 64,000 |
| 2020-02-03 | Bronfeld Zeev Director | Grant or award · Stock Options (Right to Buy) | +240,000 | 240,000 | ||
| 2020-01-20 | Granot David Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2020-01-20 | Bar-Shalev Amos Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2020-01-20 | Schwartz Aharon Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2020-01-20 | Boudes Pol F Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2020-01-20 | Melincoff Gwen A Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2019-09-22 | Rubin Eyal Sr. VP & CFO | Grant or award · Stock Options (Right to Buy) | +800,000 | 800,000 | ||
| 2019-06-30 | Bashan Dror President & CEO | Grant or award · Stock Options (Right to Buy) | +1,600,000 | 1,600,000 | ||
| 2018-09-13 | Maimon Yossi VP, Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +700,000 | 700,000 | ||
| 2018-09-13 | Almon Einat Brill SVP, Product Development | Grant or award · Stock Options (Right to Buy) | +700,000 | 700,000 | ||
| 2018-09-13 | Naos Yaron Sr. VP, Operations | Grant or award · Stock Options (Right to Buy) | +600,000 | 600,000 | ||
| 2018-09-13 | Manor Moshe President & CEO | Grant or award · Stock Options (Right to Buy) | +1,300,000 | 1,300,000 | ||
| 2018-09-13 | Shaaltiel Yoseph Executive VP, R&D | Grant or award · Stock Options (Right to Buy) | +700,000 | 700,000 | ||
| 2017-05-16 | Manor Moshe President & CEO | Purchase | +50,000 | $0.81 | $41K | 50,000 |
| 2016-12-02 | Camber Capital Management LLC 10% owner | Sale | −2,500,000 | $0.32 | $792K | 10,775,000 |
| 2016-09-15 | Shaaltiel Yoseph Executive VP, R&D | Option exercise | +122,162 | $0.00 | $122 | 585,916 |
| 2016-09-15 | Shaaltiel Yoseph Executive VP, R&D | Option exercise · Stock Options (Right to Buy) | −122,162 | 0 | ||
| 2015-12-14 | Maimon Yossi Vice President & CFO | Purchase | +10,000 | $0.78 | $8K | 10,000 |
| 2015-10-19 | Camber Capital Management LLC 10% owner | Purchase | +4,000,000 | $1.00 | $4.0M | 13,274,577 |
Page 5 of 7 · 139 trades